Gilead Sciences Inc

$19.00

Want a discount? Become a member by purchasing Annual Subscription!
SKU: GILD-1 Category:

Description

Gilead Sciences, Inc. delivered an all-around beat in the previous quarter, showcasing a 5% increase in the base business compared to the same period in 2022. Impressively, year-over-year growth reached 10% for the initial nine months of 2023. The outstanding performance of key therapies in Virology and Oncology propelled the quarter’s success. Biktarvy achieved a remarkable 12% growth from the corresponding quarter in 2022. Oncology also emerged as a growth driver. The increasing adoption of Trodelvy, a TROP-2-directed ADC, and cutting-edge cell therapies further fueled this upward trajectory. Clinical accomplishments marked another stellar quarter, with progress in Gilead’s 60 clinical programs across virology, oncology, and inflammation. Notable achievements included the European Commission’s approval of Trodelvy for pretreated hormone receptor-positive HER2-negative metastatic breast cancer, extending its global reach. Ongoing Phase III trials, such as EVOKE-03 in oncology and PURPOSE-I in HIV prevention, demonstrated Gilead’s commitment to advancing therapeutic options. Encouraging results from the Phase I study of CART-ddBCMA in multiple myeloma and promising data from HIV treatment and prevention trials added to the positive momentum. They further collaborated with Assembly Biosciences to advance the development of novel antiviral therapies. The alliance will first concentrate on Assembly Bio’s well-established areas of herpesviruses, hepatitis B virus (HBV), and hepatitis D virus (HDV).

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!